Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib +/- Irinotecan in Gastric/GEJ Cancer
NCT00061932Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Apr 2003
- Primary completion
- Dec 2009
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 2, open-label trial of bortezomib in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (2 arms), sponsored by National Cancer Institute. Primary endpoint: True Response Rate Evaluated for the Combination of Irinotecan and PS341 up to 6 years. Started Apr 2003; status: completed.
02
Drugs
bortezomib
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT00061932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00061932.